ADVANZ Pharma, sponsor for antidepressants Tofranil and Parnate, has agreed to update its consumer medicines information (CMI) and product information (PI) documents to better reflect current best practice - the first pharma to do so.
TaperMate app founder Alicia Martin revealed the news in a LinkedIn post, and is also asking other pharmas to include information on current evidence about risk of withdrawal and the need for tapering, and to remove references to the outdated chemical imbalance theory.
"This is just the beginning and I hope it encourages other companies to do the same," Martin posted.
Organon (sponsor for Avanza) has indicated it will "consider" making these updates in future CMIs, while Lundbeck (Cipramil, Lexapro & Brintellix), Pfizer (Pristiq) and Pharmaco (Anafranil), have indicated they will not be updating their documents.
Martin is still waiting to hear back from some companies.
There is a petition on the TaperMate website, and Martin told Pharmacy Daily she is hoping to get more people to sign.
"If I can show that we got significantly more signatures and that other companies have made the decision to update their documents, I may be able to convince some of the companies that have originally said 'no'," said Martin.
Learn more about the campaign HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Sep 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Sep 25
